Bharat Parenterals Ltd
Bharat Parenterals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #9 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
3 of 3 strong
The short version
Standalone business: - Expected revenue growth of 10% to 15% in FY '27, based on INR 230 crores base. Innoxel Lifesciences: Expected revenue growth of 35%-45% in FY '27 with EBITDA margins of 20%-25%.
From Bharat Parenterals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Standalone business:
- Expected revenue growth of 10% to 15% in FY '27, based on INR 230 crores base.
- Full recovery and crossing FY '25 numbers anticipated by FY '28.
- Long-term peak revenue target of INR 400-500 crores by 2030.
- Growth driven by Southeast Asia, Africa, and MENA regions.
- Innoxel Lifesciences:
- Revenue growth of 35% to 45% expected in FY '27.
- Commercial CMO supply starting Q2 FY '27 with 2-3 products commercializing.
- 10 new filings and 20 partner deals planned in FY '27.
- Strong manufacturing revenues and out-licensing milestones expected to start FY '28.
- Varenyam Healthcare:
- Revenue growth of 20% to 25% forecast in FY '27.
- Expansion of field force to over 250 people.
- Introduction of 7 new products including India's first made-in-India Sugammadex.
- Varenyam Biolifesciences:
- Pre-revenue through FY '27.
2 more points from Bharat Parenterals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Bharat Parenterals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Varenyam Biolifesciences (VBPL) is undergoing capital investment with an approved budget of around INR 160 crores for building a complex injectable manufacturing facility.
- As of FY '26 year-end, around INR 33 crores has been spent (20% of the budget).
- Key milestones include commissioning manufacturing lines by September 2027 and validation by March 2028.
- The facility aims for first regulatory filing under EUGMP in Q1 FY '29 and commercial supply by Q4 FY '29.
2 more points from Bharat Parenterals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bharat Parenterals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The standalone business has an order book of INR 171 crores, providing reasonable visibility for FY '27.
- The $27 million ($27 million approx.) tender order for high-demand pharmaceutical products in the standalone business was delayed but has started supply in 2026, with 90% expected to be covered within the year.
- Innoxel has 20 targeted new partner deals in the pipeline, with 10 in advanced stages of discussions and due diligence.
- Innoxel expects to file 10 new products in FY '27.
2 more points from Bharat Parenterals Ltd's call on order book
Create a free account to keep reading this call
Bharat Parenterals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹100 Cr, net loss ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bharat Parenterals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Bharat Parenterals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Bharat Parenterals Ltd Q4 FY26 results?
Standalone business: - Expected revenue growth of 10% to 15% in FY '27, based on INR 230 crores base. Innoxel Lifesciences: Expected revenue growth of 35%-45% in FY '27 with EBITDA margins of 20%-25%.
What is Bharat Parenterals Ltd share price analysis?
Bharat Parenterals Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of N/A with a market cap of ₹1,007 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bharat Parenterals Ltd planning capital expenditure?
Varenyam Biolifesciences (VBPL) is undergoing capital investment with an approved budget of around INR 160 crores for building a complex injectable manufacturing facility. - As of FY '26 year-end, around INR 33 crores has been spent (20% of the budget). - Key milestones include commissioning manufacturing lines by September 2027 and validation by March 2028. - The facility aims for first regulatory filing under EUGMP in Q1 FY '29 and commercial supply by Q4 FY '29. - Standalone business completed facility upgrades last year including general injectable vial line, water system in beta-lactam block, preparing for upcoming PIC/S and EUGMP inspections in FY '27.
Keep Bharat Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.